◆ 会议时间：2022年12月1日至3日
◆ 会议地点：美国 洛杉矶Los Angeles

◆ 会议简介：

2022年第20届世界胰岛素抵抗、糖尿病和心血管疾病大会(WCIRDC)将于2022年12月1日至3日在美国洛杉矶举行。世界胰岛素抵抗、糖尿病和心血管疾病大会(WCIRDC)是由代谢内分泌教育基金会(MEEF)主办的一个独特的多学科会议。WCIRDC是首屈一指的致力于糖尿病、肥胖、脂质、心血管疾病（CVD）和能量平衡宣的全球会议，并将基础研究与临床实践联系起来，预计有500余名代表参加本次会议。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

20th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Date: December 1-3, 2022
Venue: Hilton Universal Hotel, Los Angeles, CA, USA

Theme: Exploring New Frontiers In Metabolism - Tomorrow's Clinical Science Today

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 20th year, is a unique and exciting multidisciplinary CME conference. The Congress has become the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

WCIRDC 2022 will return to Live in Person meeting at the Hilton Universal City Hotel in Los Angeles, on December 1-3, 2022. The conference will also have a virtual component- Streaming Live online followed by 90 days On Demand.

WCIRDC is the only meeting of its size combining basic and clinical science. For two decades it has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside- to-bench. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty. In an intimate setting, for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, obesity, CVD, the Congress’ focus has expanded to cover the kidney, liver, brain, bone, cancer, and more. The congress addresses dyslipidemia, atherosclerosis, hypertension, hypercoagulation, inflammation, and energy metabolism. It provides the newest clinical updates on pharmaceutical interventions such as GLP1ra, SGLT2i’s, PCSK9i’s, MRA and EPA to name a few. The goal is to understand the state-of-the-art pathophysiology, new medical interventions, and to develop appropriate comprehensive clinical management strategies.

To make basic and clinical research topics relevant to clinical medicine, following each session there will be live Q&A and a discussion on implications to clinical practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of live panel, providing summary of the day, commentary, and open for Q&A.

The Congress attracts state-of-the-art abstracts attracting, young up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be published in Metabolism, a peer-reviewed journal and also available for 90 days on demand,

The congress is featured by many media outlets with proceedings featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes and its complications and others.

Program Objectives

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions; focusing on basic science such as insulin resistance, fat cells, inflammation, and on clinical practice; understanding the comprehensive management cardiorenalmetabolic conditions.

Upon completion of this meeting, participants should be able to:

• Discuss COVID-19 in diabetes and Obesity.
• Describe the relationship between diabetes, obesity, and heart failure
• Discuss T1D obesity and CVD
• Discuss the role of the beta cells in diabetes
• Discuss the role of fat cells in the development of cardiometabolic conditions
• Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes
• Provide the traditional comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia.
•  Highlight the paradigm shift in management focusing on preventing the next evet of ASCVD, HF and CKD
• Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD.
• Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD
• Address SGLT2i role in managing patients with CKD and HFrEF & HFpEF
• Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
• Discuss fatty liver disease and its relationship to diabetes and CVD
• Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
• Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
• Technology in monitoring and reducing DM & ASCVD
• Address the multispecialty practice recommendations to managing patients with cardiorenalmetabolic diseases

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。